Meta-analysis of cutaneous adverse events and cancer survival prognosis with immune checkpoint inhibitor treatment

Recent research suggests that the prevalence of cutaneous immune-related adverse events (cirAEs) is associated with favorable outcomes among cancer patients who receive immune checkpoint inhibitor (ICI) treatment. Researchers at Southeast University (Nanjing, China) conducted a systematic review and meta-analysis of 23 studies with a total of 22,749 cancer patients treated with ICIs. Patients with cirAEs had longer overall and progression-free survival. Consistent associations were observed across all subgroups stratified by cirAE subtype, study design, geographic region, ICI type, and cancer type, except for PFS analysis in the USA. The authors conclude that cirAEs may have prognostic value during ICI treatment.